An observational, prospective cohort study to evaluate the long-term safety and efficacy of infliximab SC in patients with Crohn's disease, Ulcerative colitis in Korea

Chung-Ang Univerisity Hospital0 个研究点目标入组 1,500 人开始时间: 待定最近更新: 2023年12月19日

试验速览

暂无简介。

•1) Patients diagnosed with moderate-severe inflammatory bowel disease (Cron's disease or ulcerative colitis)
•2) a patient over the age of 19
•3) Any person who intends to administer a subcutaneous injection of Remsima under the authorization of this drug
•4) a person who voluntarily agreed in writing to this study
•5) It is recommended that women of childbearing age perform appropriate contraception to prevent pregnancy and contraception for at least 6 months after the final administration of the Remsima subcutaneous injection. The implementation of contraception can be determined after discussion with the researcher based on risks and benefits.

•1) A person who is prohibited from being administered as specified in the product description of this drug
•2) Pregnant or lactating women
•3) Patients who are unfit to participate in the study according to the researcher's judgment

发起方

Chung-Ang Univerisity Hospital